LABD vs XBIX: Leverage, Returns & Decay

Over three months to Nov 13, 2026, against its daily multiple, compounded, LABD finished 3.8 points over and XBIX 2.6 points short.

Return gap
+13.0 pts3 months to Nov 13, 2026: LABD ahead, total return
Fee gap
0.62 ptsA year: LABD 1.07%, XBIX 0.45%, per filings dated Mar 3, 2026 and Jun 11, 2026
Overlap
–No book read for both funds
Net flow
–Needs daily flows for both funds
The answerOne drawing that carries it.

Compare two other funds

The evidenceWhy, in charts and cards.
LABD and XBIX · 3 months

Growth of 100

LABD −0.9%XBIX −13.9%
Growth of 100 in LABD and XBIX over 3 months, Aug 14, 2026 to Nov 13, 2026, with distributions reinvested. LABD ends at 99.1 (−0.9%), XBIX at 86.1 (−13.9%).

LABD −0.9%, XBIX −13.9%: LABD +13.0 pts ahead, 3 months, Aug 14, 2026 to Nov 13, 2026.

Share

Use this comparison

Alert

LABD flows, by email on Sundays.

One-click unsubscribe. See Privacy.

Hypothetical · drag to set

Fees over time

Hypothetical. $10,000 in LABD for 10 years at 1.07% a year costs about $1,728 in fees and lost growth; XBIX at 0.45% would cost $746. Assumes 6% a year before fees, a sample rate, not a forecast.

How each fund moved

LABD · 3 months to Nov 13, 202614.1 pts short of its stated multiple
14.1 pts short of its stated multipleLABD returned −0.9% while −3 times XBI's move would have been +13.2%. Data from Aug 14, 2026 to Nov 13, 2026.XBI −4.4% ×−3 implies+13.2%LABD returned−0.9%14.1 pts short of its stated multipleLABD returned −0.9% while −3 times XBI's move would have been +13.2%. Data from Aug 14, 2026 to Nov 13, 2026.XBI −4.4% ×−3 implies+13.2%LABD returned−0.9%

LABD returned −0.9% while −3 times XBI's move would have been +13.2%. Data from Aug 14, 2026 to Nov 13, 2026.

LABD returned −0.9% while −3 times XBI's move would have been +13.2%. Data from Aug 14, 2026 to Nov 13, 2026.
XBIX · 3 months to Nov 13, 20265.1 pts short of its stated multiple
5.1 pts short of its stated multipleXBIX returned −13.9% while 2 times XBI's move would have been −8.8%. Data from Aug 14, 2026 to Nov 13, 2026.XBI −4.4% ×2 implies−8.8%XBIX returned−13.9%5.1 pts short of its stated multipleXBIX returned −13.9% while 2 times XBI's move would have been −8.8%. Data from Aug 14, 2026 to Nov 13, 2026.XBI −4.4% ×2 implies−8.8%XBIX returned−13.9%

XBIX returned −13.9% while 2 times XBI's move would have been −8.8%. Data from Aug 14, 2026 to Nov 13, 2026.

XBIX returned −13.9% while 2 times XBI's move would have been −8.8%. Data from Aug 14, 2026 to Nov 13, 2026.

IQ Leverage Score

How closely it delivered its daily multiple over 3 months, ranked against 19 inverse ETFs at 3x, over three months and 498 leveraged ETFs at 2x, over three months. 100 is best.

XBIX scores higher · Did it keep up with its own daily multiple, compounded day by day, over three months?

LABD among the 19 inverse ETFs at 3x, over three months

2.6, the lowest in this set97.4, the highest

XBIX among the 498 leveraged ETFs at 2x, over three months

0.1, the lowest in this set99.9, the highest

A percentile among the 19 inverse ETFs at 3x, over three months. XBIX is a percentile among the 498 leveraged ETFs at 2x, over three months, a different set, so the two marks are not on one scale. Three months only, against the fund's own daily multiple; a different quarter can rank it very differently.

Key numbers

LABD returned, 3 months
−0.9%
XBIX returned, 3 months
−13.9%
LABD from its stated multiple: compounding −17.9 pts, gap to the daily multiple +3.8 pts
−14.1 pts
XBIX from its stated multiple: compounding −2.5 pts, gap to the daily multiple −2.6 pts
−5.1 pts

XBIX costs 0.62 points a year less.

Pair scorecard

Open the table

Points (pts) are percentage points.

Total return, 1 year−72.8%not published
What its daily multiple gave, 3 months−4.7%−11.3%
What it tracksS&P BiotechU.S. Biotech
Expense ratio1.07%0.45%
Net assets, as of Nov 12, 2026$79m$317,675
Holdings in commonnot published

The numbers behind it

Net assets: $79m on Nov 12, 2026 for Direxion Daily S&P Biotech Bear 3X ETF, and $314,629 on Nov 13, 2026 for Corgi U.S. Biotech 2x Daily ETF.

Side by side

Open the table
FundDirexion Daily S&P Biotech Bear 3X ETF · Aims to return three times the opposite of the daily move of biotech (XBI)Corgi U.S. Biotech 2x Daily ETF · Aims to return twice the daily move of biotech (XBI)
IssuerDirexionCorgi
Sets out to return−3x+2x
Underlying assetXBIXBI
Segmentsectorsector
Fund returned, 3 months−0.9%−13.9%
Underlying returned, over that window−4.4%−4.4%
What the stated multiple implies, over that window+13.2%−8.8%
Difference from stated, over that window−14.1 pts−5.1 pts
Fund returned, 1 year−72.8%+22.0% (since launch, Jun 3, 2026)
Difference from stated, over that windownot available−10.2 pts (since launch, Jun 3, 2026)
Underlying volatility35%35%
Expense ratio1.07%0.45%
First tradedMay 28, 2015Jun 3, 2026
Net assets, LABD as of Nov 12, 2026 and XBIX as of Nov 13, 2026$79m$314,629

As of Nov 13, 2026. Source: ETFIQ.

The dataFull tables, method and files, one click away.

Window by window

Open the full table
1 month−14.1%+2.8%−7.8%+5.2%−6.3 pts−2.4 pts
3 months−0.9%−13.9%+13.2%−8.8%−14.1 pts−5.1 pts
6 months−48.9%–−45.9%–−3.0 pts–
1 year−72.8%–not meaningful–not meaningful–
3 years−96.0%–not meaningful–not meaningful–
Since launch (Not the same days: LABD May 2015 · XBIX Jun 2026)−100.0%+22.0%not meaningful+32.2%not meaningful−10.2 pts

– means no data for this window.

About LABD

Over the three months to Nov 13, 2026, LABD lost 0.9%, against −4.7% for three times the inverse of XBI's daily moves. Read the multiple against the whole window instead and −3 times XBI's −4.4% implies +13.2%, which makes LABD look 14.1 points short. That is not the fund's objective, which is daily. Of that 14.1, daily compounding is −17.9 points, which any −3 times fund would show over the same path, and the fund itself is +3.8 points against −3 times each day's move, compounded. LABD aims to return -3 times XBI's move each day, then resets. Over one day it does that. Over longer periods the daily results compound, so the total is not -3 times the period's move: it is lower after a fall and recovery, and can be higher in a steady run. XBI moved at 35% annualized over that window. The more it moves, the further the two numbers separate.

About XBIX

Over the three months to Nov 13, 2026, XBIX lost 13.9%, against −11.3% for twice XBI's daily moves. Read the multiple against the whole window instead and 2 times XBI's −4.4% implies −8.8%, which makes XBIX look 5.1 points short. Of that 5.1, daily compounding is −2.5 points, which any 2 times fund would show over the same path, and the fund itself is −2.6 points against 2 times each day's move, compounded. XBIX aims to return +2 times XBI's move each day, then resets. Over longer periods the daily results compound, so the total is not +2 times the period's move: it is lower after a fall and recovery, and can be higher in a steady run.

Questions people ask

Which came closer to its daily multiple, LABD or XBIX?

Over the window to Nov 13, 2026, LABD finished 14.1 points from what its multiple implies and XBIX finished 5.1 points from its own, so XBIX came closer. Neither number predicts the next window: it depends on how much the underlying moves about.

Are LABD and XBIX levered on the same thing?

Yes. Both are levered on biotech, LABD at -3 times and XBIX at +2 times the daily move.

Which one decays faster, LABD or XBIX?

Decay follows how much the underlying moves about. Over this window LABD’s moved at 35% annualized and XBIX’s at 35%, so LABD has the rougher ride and, at the same multiple, loses more to compounding.

Can I hold LABD or XBIX for a year?

Both reset every day, so the multiple in the name applies to a single day, and daily results compound. Over a year the total is not the multiple times the year’s move; after a fall and recovery it is lower.

Which is cheaper, LABD or XBIX?

LABD charges 1.07% a year and XBIX charges 0.45%, so XBIX is cheaper. Fees come from each fund's prospectus.

Other comparisons

Sources

More

Links are sources, not endorsements. A comparison is not a recommendation.

Copy and cite

Cite this pageCitation, APA and Markdown

ETFIQ, LABD against XBIX, data as of Nov 13, 2026. https://etfiq.com/compare/leverage/labd-vs-xbix

Open data

Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.